Literature DB >> 27793910

Highly Halaven-resistant KBV20C Cancer Cells Can Be Sensitized by Co-treatment with Fluphenazine.

Ji Hyun Cheon1, Byung Mu Lee1, Hyung Sik Kim2, Sungpil Yoon2.   

Abstract

AIM: To identify conditions that induce an increase in the sensitivity of highly Halaven (HAL)-resistant cancer cells compared to sensitive cells.
MATERIALS AND METHODS: We observed that drug-resistant KBV20C cells are highly resistant to HAL compared to other antimitotic drugs. The concentration required to treat KBV20C cells was almost 500-fold higher than that used to treat sensitive parent KB cells. In order to increase sensitization, HAL-treated KBV20C cells were co-treated with the repositioned drug, fluphenazine (FLU).
RESULTS: HAL and FLU co-treatment inhibited the growth and increased apoptosis via G2 arrest in HAL-treated KBV20C cancer cells. Sensitization by HAL-FLU affected retinoblastoma protein (pRB), pHistone H3 and pH2AX protein levels. FLU could also inhibit p-glycoprotein (P-gp) activity in HA-resistant KBV20C cells. These observations suggest that the mechanisms underlying FLU-HAL sensitization in resistant KBV20C cells involve both apoptosis and P-gp inhibition. Furthermore, both thioridazine (THIO) and mefloquine (MEF), but not azathioprine (AZA), sensitized HAL-treated KBV20C cells.
CONCLUSION: These findings provide important information regarding the sensitization of HAL-resistant cells and indicate that FLU, THIO and MEF may have similar sensitization effects in highly HAL-resistant cells. Copyright
© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  Halaven; P-gp; drug-resistance; fluphenazine; mefloquine; thioridazine

Mesh:

Substances:

Year:  2016        PMID: 27793910     DOI: 10.21873/anticanres.11172

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  3 in total

1.  JAK2 Inhibitor, Fedratinib, Inhibits P-gp Activity and Co-Treatment Induces Cytotoxicity in Antimitotic Drug-Treated P-gp Overexpressing Resistant KBV20C Cancer Cells.

Authors:  Yunmoon Oh; Jin-Sol Lee; Ji Sun Lee; Jae Hyeon Park; Hyung Sik Kim; Sungpil Yoon
Journal:  Int J Mol Sci       Date:  2022-04-21       Impact factor: 6.208

Review 2.  Drug Repositioning With an Anticancer Effect: Contributions to Reduced Cancer Incidence in Susceptible Individuals.

Authors:  Sungpil Yoon; Hyung Sik Kim
Journal:  In Vivo       Date:  2021 Nov-Dec       Impact factor: 2.155

3.  Low-Dose Crizotinib, a Tyrosine Kinase Inhibitor, Highly and Specifically Sensitizes P-Glycoprotein-Overexpressing Chemoresistant Cancer Cells Through Induction of Late Apoptosis in vivo and in vitro.

Authors:  Kyeong Seok Kim; Chunxue Jiang; Ji Young Kim; Jae Hyeon Park; Hae Ri Kim; Su Hyun Lee; Hyung Sik Kim; Sungpil Yoon
Journal:  Front Oncol       Date:  2020-05-12       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.